SR One Capital Management LP Makes New $1.29 Million Investment in enGene Holdings Inc. $ENGN

SR One Capital Management LP acquired a new stake in shares of enGene Holdings Inc. (NASDAQ:ENGN) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 747,750 shares of the company’s stock, valued at approximately $1,293,607. enGene makes up 0.0% of SR One Capital Management LP’s investment portfolio, making the stock its 15th biggest position. SR One Capital Management LP owned 1.12% of enGene as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Cresset Asset Management LLC acquired a new position in shares of enGene in the 2nd quarter valued at approximately $36,000. Paloma Partners Management Co purchased a new position in enGene during the 2nd quarter valued at about $38,000. Raymond James Financial Inc. increased its stake in enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares in the last quarter. Citadel Advisors LLC grew its holdings in enGene by 153.3% during the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after purchasing an additional 35,327 shares during the period. Finally, Millennium Management LLC raised its stake in enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after purchasing an additional 7,472 shares in the last quarter. Institutional investors own 64.16% of the company’s stock.

Wall Street Analysts Forecast Growth

ENGN has been the subject of several research reports. Leerink Partners lowered enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price objective for the company. in a research note on Friday, May 8th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $2.00 price target (down from $25.00) on shares of enGene in a report on Friday, May 8th. HC Wainwright cut their price target on enGene from $6.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of enGene in a research note on Wednesday, August 12th. Finally, Citizens Jmp downgraded enGene from an “outperform” rating to a “market perform” rating in a report on Friday, May 8th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, enGene has a consensus rating of “Hold” and a consensus price target of $11.05.

enGene Price Performance

Shares of NASDAQ:ENGN traded down $0.07 during mid-day trading on Friday, reaching $1.83. The stock had a trading volume of 266,901 shares, compared to its average volume of 1,018,531. The company has a current ratio of 12.57, a quick ratio of 12.57 and a debt-to-equity ratio of 0.10. The company has a market cap of $122.93 million, a P/E ratio of -0.85 and a beta of -0.28. The business’s 50 day moving average price is $1.81 and its 200 day moving average price is $4.50. enGene Holdings Inc. has a 1 year low of $1.40 and a 1 year high of $12.25.

enGene (NASDAQ:ENGN) last posted its earnings results on Monday, June 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. During the same quarter in the previous year, the business earned $0.51 EPS. Research analysts expect that enGene Holdings Inc. will post -1.84 EPS for the current fiscal year.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.